Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes

Bibliography

• Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38(3):376-83
   PubMed Web of Science ®Google Scholar
• Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37(3):740-50
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35(7):1473-8
   PubMed Web of Science ®Google Scholar
• Strojek K, Yoon KH, Hruba V, et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014;5(1):267-83
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223-33
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32(9):1649-55
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13(6):567-76
   PubMed Web of Science ®Google Scholar
• Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94(12):4810-19
   PubMed Web of Science ®Google Scholar
• Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012;28(4):513-23
   PubMed Web of Science ®Google Scholar
• Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract 2014;20(11):1187-97
   PubMed Web of Science ®Google Scholar
• Vakkalagadda B, Vetter M, Rana J, et al. Bioequivalence (BE) of Saxaglitpin (SAXA)/Dapagliflozin (DAPA) Fixed Dose Combination (FDC) Tablets Compared with Co-administration of the Individual Tablets. Diabetes 2015;64(Suppl 1):1254-P
   Google Scholar
• Matthaei S, Catrinoiu D, Celinski A, et al. A Randomized, Double-Blind Trial of Saxagliptin Add-on to Dapagliflozin and Metformin. Diabetes 2015;64(Suppl 1):104-OR
   PubMed Web of Science ®Google Scholar
• Matthaei S, Ranetti AE, Danshi L, et al. A Randomized, Double-Blind Phase 3 Trial of Dapagliflozin Add-on to Saxagliptin and Metformin in Type 2 Diabetes. Diabetes 2015;64(Suppl 1):105-OR
   Google Scholar
• Blonde L, Sheehan JJ, Garcia-Sanchez R, Barrett UC. Quality Measure Thresholds with Saxagliptin (SAXA) and Dapagliflozin (DAPA) Dual Therapy vs. Individual Commponents as Add-on to Metformin (MET). Diabetes 2015;64(Suppl 1):1228-P
   Google Scholar
• The National Quality Forum. Available from: www.qualityforum.org/Home.aspx [Last accessed 12th June 2015]
   Google Scholar
• Sjostrom CD, Johansson P, Ptaszynska A, et al. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res 2015;12(5):352-8
   PubMed Web of Science ®Google Scholar
• Ekholm E, Hansen L, Iqbal N, et al. Combined Treatment with Saxagliptin and Dapaglflozin improves Beta-cell Function and reduces Insulin levels by Increased Insulin Clearance. Diabetes 2015;64(Supp 1):1223-P
   Google Scholar
• Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015;38(3):365-72
   PubMed Web of Science ®Google Scholar
• Rohwedder K, Ekholm E, Cook W, et al. Dual Treatment with Saxagliptin and Dapgliflozin Provides a Similar Increase in Urinary Glucose Excretion With Fewer Genitourinary Infections Compare with Dapagliflozin. Diabetes 2015;64(Suppl 1):1208-P
   Google Scholar
• Bloomgarden Z. Sodium-glucose cotransporter 2 inhibitors and renal function-2. Journal of diabetes 2015;7(3):295-8
   PubMedGoogle Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34(9):2015-22
   PubMed Web of Science ®Google Scholar
• Min T, Handley J, Williams D, et al. Renal function and dapagliflozin in routine clinical practice. J Diabetes 2015;7(4):591-2
   PubMedGoogle Scholar
• Vakkalagadda B, Lubin S, Reynolds L, et al. Lack of Pharmacokinetic Interaction between Saxagliptin and Dapagliflozin in Health Subjects. Diabetes 2015;64(Suppl 1):1256-P
   Google Scholar